Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors
Author(s) -
Cecilie Heegaard Brahe,
Simon Krabbe,
Mikkel Østergaard,
Lykke Midtbøll Ørnbjerg,
Daniel Glinatsi,
Henrik Røgind,
Hanne Jensen,
Annette Hansen,
Jesper Nørregaard,
Søren Jacobsen,
Lene Terslev,
Tuan Khai Huynh,
Dorte Vendelbo Jensen,
Natalia Manilo,
Karsten Asmussen,
Per Brown Frandsen,
Mikael Boesen,
Zoreh Rastiemadabadi,
Lone Morsel Carlsen,
J. Møller,
Niels Steen Krogh,
Merete Lund Hetland
Publication year - 2018
Publication title -
lara d. veeken
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/key244
Subject(s) - medicine , tapering , discontinuation , rheumatoid arthritis , interquartile range , cohort , guideline , tnf inhibitor , etanercept , surgery , computer graphics (images) , pathology , computer science
A cohort of routine care RA patients in sustained remission had biological DMARD (bDMARDs) tapered according to a treatment guideline. We studied: the proportion of patients whose bDMARD could be successfully tapered or discontinued; unwanted consequences of tapering/discontinuation; and potential baseline predictors of successful tapering and discontinuation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom